Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research.
Department of Economics, Keio University, Minato city, Tokyo, Japan.
Int J Surg. 2024 Mar 1;110(3):1770-1780. doi: 10.1097/JS9.0000000000000998.
Partial pancreatectomy, commonly used for chronic pancreatitis, or pancreatic lesions, has diverse impacts on endocrine and metabolism system. The study aims to determine the global prevalence of new-onset, worsening, and resolution of diabetes following partial pancreatectomy.
The authors searched PubMed, Embase, Web of Science, and Cochrane Library from inception to October, 2023. DerSimonian-Laird random-effects model with Logit transformation was used. Sensitivity analysis, meta-regression, and subgroup analysis were employed to investigate determinants of the prevalence of new-onset diabetes.
A total of 82 studies involving 13 257 patients were included. The overall prevalence of new-onset diabetes after partial pancreatectomy was 17.1%. Univariate meta-regression indicated that study size was the cause of heterogeneity. Multivariable analysis suggested that income of country or area had the highest predictor importance (49.7%). For subgroup analysis, the prevalence of new-onset diabetes varied from 7.6% (France, 95% CI: 4.3-13.0) to 38.0% (UK, 95% CI: 28.2-48.8, P <0.01) across different countries. Patients with surgical indications for chronic pancreatitis exhibited a higher prevalence (30.7%, 95% CI: 21.8-41.3) than those with pancreatic lesions (16.4%, 95% CI: 14.3-18.7, P <0.01). The type of surgical procedure also influenced the prevalence, with distal pancreatectomy having the highest prevalence (23.7%, 95% CI: 22.2-25.3, P <0.01). Moreover, the prevalence of worsening and resolution of preoperative diabetes was 41.1 and 25.8%, respectively.
Postoperative diabetes has a relatively high prevalence in patients undergoing partial pancreatectomy, which calls for attention and dedicated action from primary care physicians, specialists, and health policy makers alike.
部分胰腺切除术常用于治疗慢性胰腺炎或胰腺病变,其对内分泌和代谢系统有多种影响。本研究旨在确定部分胰腺切除术后新发、恶化和缓解糖尿病的全球患病率。
作者检索了 PubMed、Embase、Web of Science 和 Cochrane Library 自成立至 2023 年 10 月的文献。采用 DerSimonian-Laird 随机效应模型和 Logit 转换。采用敏感性分析、Meta 回归和亚组分析来研究新诊断糖尿病患病率的决定因素。
共纳入 82 项研究,共计 13257 例患者。部分胰腺切除术后新发糖尿病的总体患病率为 17.1%。单变量 Meta 回归表明,研究规模是异质性的原因。多变量分析表明,国家或地区的收入具有最高的预测重要性(49.7%)。对于亚组分析,不同国家的新诊断糖尿病患病率从 7.6%(法国,95%CI:4.3-13.0)到 38.0%(英国,95%CI:28.2-48.8,P<0.01)不等。有慢性胰腺炎手术适应证的患者的患病率较高(30.7%,95%CI:21.8-41.3),而胰腺病变患者的患病率较低(16.4%,95%CI:14.3-18.7,P<0.01)。手术方式也影响了患病率,其中远端胰腺切除术的患病率最高(23.7%,95%CI:22.2-25.3,P<0.01)。此外,术前糖尿病恶化和缓解的患病率分别为 41.1%和 25.8%。
部分胰腺切除术后糖尿病的患病率相对较高,这需要初级保健医生、专家和卫生政策制定者共同关注和采取行动。